Indivior (INDV) Projected to Announce Earnings on ThursdayDefense World · 2 days ago
Indivior to Report Third Quarter 2026 Financial ResultsGlobeNewsWire · 5 days ago
Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $45.17Defense World · 6 days ago
Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)Defense World · Sep 25, 2026
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNBusiness Wire · Sep 24, 2026
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNBusiness Wire · Sep 24, 2026Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | $0.87 | $1.15 | Beat |
| Apr 30, 2026 | $0.64 | $0.96 | Beat |
| Feb 26, 2026 | $0.65 | $0.82 | Beat |
| Oct 30, 2025 | $0.38 | $0.72 | Beat |
| Jul 31, 2025 | $0.26 | $0.51 | Beat |
| Apr 24, 2025 | $0.22 | $0.41 | Beat |